BRIDGEWATER, N.J., June 29, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that theCompany will release its second quarter 2018 financial results on Thursday, August 9, 2018, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community
The financial results and live webcast will be accessible through the Investor Relations section of the Company's Web site at https://investors.amneal.com.
To access the call through a conference line, dial (877) 356-3814 (in the U.S.) and (706) 758-0033 (international callers). The conference ID is 3045719.
A replay of the conference call will be available for seven days shortly after the call. To access the replay, dial (855) 859-2056 (in the U.S.) and (404) 537-3406 (international callers). The access code for the replay is 3045719.
About Amneal Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is an integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has approximately 6,500 employees in its operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
Amneal is one of the largest and fastest growing generic pharmaceutical manufacturers in the United States, with an expanding portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. The Company markets a portfolio of branded pharmaceutical products through its Impax Specialty Pharma division focused principally on central nervous system disorders and parasitic infections. For more information, visit www.amneal.com.
Contact: Mark Donohue Investor Relations and Corporate Communications (215) 558-4526 www.amneal.com
View original content:http://www.prnewswire.com/news-releases/amneal-to-report-second-quarter-2018-results-on-august-9-2018-300674598.html
SOURCE Amneal Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Moxetumomab pasudotox-tdfk is used to treat hairy cell leukemia (a form of chronic lymphocytic ...
Complex regional pain syndrome (CRPS) is rare chronic pain disorder usually involving an arm or ...
Polyarthritis refers to pain in four or more joints simultaneously due to various causes ranging ...View All